SOLICITATION NOTICE
R -- Value of research statistical software tool to determine the promise of genome-based applications
- Notice Date
- 7/27/2012
- Notice Type
- Presolicitation
- NAICS
- 561210
— Facilities Support Services
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd., EPS Suite 600, Rockville, Maryland, 20852
- ZIP Code
- 20852
- Solicitation Number
- NCI-120123-TG
- Archive Date
- 8/25/2012
- Point of Contact
- Terry Galloway, Phone: 301-402-4509, Caren N Rasmussen, Phone: (301) 402-4509
- E-Mail Address
-
gallowaytl@mail.nih.gov, cr214i@nih.gov
(gallowaytl@mail.nih.gov, cr214i@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- Contracting Office Address Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd. EPS Room 6074, Rockville, MD, 20852, UNITED STATES Description The National Cancer Institute (NCI), Division of Cancer Control and Population Sciences (DCCPS), Clinical and Translational Epidemiology Branch (CTEB) plans to procure on a sole source basis value of research (VOR) statistical software tool from Emory University, 1599 Clifton Rd. NE, 4th Floor, Atlanta, GA 30322-4250. This acquisition will be processed in accordance with simplified acquisition procedures as stated in FAR Part 13.106-1(b)(1). The North American Industry Classification System code is 541990 and the business size standard is $7.0 million. Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract. Period of Performance shall be from award through twelve (12) months. It has been determined there are no opportunities to acquire green products or services for this procurement. One of the primary functions of the CTEB is to plan, develop, direct, coordinate, and evaluate a program of epidemiologic research to improve health outcomes by developing and disseminating evidence-based information to patients, clinicians, and other stakeholders, about which interventions are most effective for which patients under specific circumstances. Because most genomic applications are unlikely to improve clinical outcome, it is imperative that new approaches be developed to indicate which potential applications might be clinically relevant and warrant further investigation in empirical studies. This project proposes a new modelling approach to characterize and identify promising applications. Information gained from this project will inform NCI to plan and prioritize future research in population-based studies and clinical prevention and treatment trials. This project will involve a series of three case studies for which VOR will be conducted to inform research priorities of genomic technologies related to cancer prevention and treatment. The application of decision analysis and value of information analysis to three representative case studies (e.g., screening, prevention, and treatment) will involve three core tasks to be completed: (i) the synthesis of evidence from a variety of sources and a probabilistic analysis to characterize the current decision uncertainty; (ii) the construction of a decision analytic model to represent the clinical decision problem being considered and estimate of the value of additional information through research to reduce decision uncertainty; and (iii) the development of a user friendly statistical software package that includes three separate VOR models for each health care case study. This software (based on three representative case studies) will allow extramural investigators to analyze the value of research for a large number of emerging and future genomic technologies related to cancer screening, prevention, and treatment. This project requires expertise in epidemiology, genomic applications in health care, an understanding of how to assess genetic risk prediction models (e.g., using metrics such as area under the receiver operating curve), statistical modeling, and software development to develop value of research models. Emory University's extensive knowledge and experience in methodological research on the development of metrics that assess genetic risk models make them uniquely qualified to facilitate the work in developing value of research models. They are currently working on a project that aims to investigate measures of usefulness of genomic profiling in risk differentiation and is an extension of previous work on developing a model to estimate the discriminative accuracy of genomic profiling. Emory also has experience developing software tools, such as PredictABEL, which assess the performance of risk models and also constructs a simulated dataset that contains individual genotype data, estimated genetic risk, and disease status, used for the evaluation of genetic risk models. The expertise and skills found at Emory University will enhance NCI's ability to allocate research resources to the most promising genomic supplications in screening, prevention and treatment of cancer. Emory University currently employees Dr. Janssens and a team of scientists who are uniquely qualified for the work that needs to be done. Dr. Janssens and her team have had rigorous training in epidemiology, technology assessment and statistics, and have extensive experience and intimate knowledge of genetic risk prediction. Her research focuses on the translation of genomic research to applications in health care, with a particular emphasis on assessment of predictive ability and health care utility of genetic risk prediction. She has published over 130 research articles and book chapters, and has given over 70 invited lectures and seminars over the past 5 years on these topics. Dr. Janssens also chairs the Dutch Association for Community Genetics and Public Health Genomics and Genetic Epidemiology. This notice is not a request for competitive quotation. However, if any interested party believes it can meet the above requirement, it may submit a statement of capabilities. The statement of capabilities and any other information furnished must be in writing and must contain material in sufficient detail to allow NCI to determine if the party can perform the requirement. Capability statements must be received in the contracting office by 11:00 AM EST, on August 10, 2012. For further information, please contact Terry Galloway, Contract Specialist via electronic mail at gallowaytl@mail.nih.gov. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted. No faxed or emailed capability statements will be accepted. In order to receive an award, contractors must be registered and have valid certification in the Central Contractor Registration (CCR) and the Online Representations and Certifications Applications (ORCA). Reference: NCI-120123-TG on all correspondence.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/NCI-120123-TG/listing.html)
- Record
- SN02819048-W 20120729/120728001142-e0d1b65fd74f17f60ad96163df178e7d (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |